Targeting Immune-Mediated Melanocyte Loss in Vitiligo: Advancing Anti- CXCL10 Therapy From Mechanistic Rationale to Phase II Readiness

• Advancing a first-in-class monoclonal antibody targeting CXCL10 to interrupt melanocyte apoptosis and T-cell recruitment, addressing a core pathogenic driver of vitiligo rather than symptomatic repigmentation alone
• Translating strong mechanistic and preclinical rationale into a capital efficient early clinical strategy, including IV proof-of-concept studies and planned transition toward subcutaneous delivery ahead of Phase II
• Navigating trial-design and feasibility considerations in vitiligo, including learning from recent Phase II failures, optimizing site selection, and strengthening signal detection in a disease area with historically mixed clinical outcomes

Speakers:

Par Nijhawan

Chief Executive Officer & Co-Founder

​​Edesa Biotech Inc.